The feasibility of using glycosylated recombinant human granulocyte colonystimulating factor (G-CSF) to increase the planned dose intensity of doxorubicin; cyclophosphamide and etoposide (ACE) in the treatment of small cell lung cancer
- 31 December 1995
- journal article
- Published by Elsevier in European Journal Of Cancer
- Vol. 31 (2) , 152-156
- https://doi.org/10.1016/0959-8049(94)00416-3
Abstract
No abstract availableKeywords
This publication has 11 references indexed in Scilit:
- A randomised trial of three or six courses of etoposide cyclophosphamide methotrexate and vincristine or six courses of etoposide and ifosfamide in small cell lung cancer (SCLC). I: Survival and prognostic factorsBritish Journal of Cancer, 1993
- Granulocyte and granulocyte-macrophage colony-stimulating factorsThe Lancet, 1993
- Escalating drug delivery in cancer chemotherapy: A review of concepts and practice —Part 2Annals of Oncology, 1993
- Escalating drug delivery in cancer chemotherapy: A review of concepts and practice – Part 1Annals of Oncology, 1993
- Recombinant granulocyte colony stimulating factor reduces the infectious complications of cytotoxic chemotherapyEuropean Journal Of Cancer, 1993
- G-CSF and liver toxicity in a patient with neuroblastomaThe Lancet, 1992
- Reduction by Granulocyte Colony-Stimulating Factor of Fever and Neutropenia Induced by Chemotherapy in Patients with Small-Cell Lung CancerNew England Journal of Medicine, 1991
- DIFFERENTIAL EFFECT OF G-CSF AND GM-CSF IN ACQUIRED CHRONIC NEUTROPENIABritish Journal of Haematology, 1991
- Dose intensity in cancer chemotherapyBritish Journal of Cancer, 1990
- Duration of chemotherapy in small cell lung cancer: a Cancer Research Campaign trialBritish Journal of Cancer, 1989